Kirmani Bilal H, Jones Sion G, Malaisrie S C, Chung Darryl A, Williams Richard Jnn
Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, Merseyside, UK, L14 3PE.
Division of Cardiac Surgery, Northwestern University, 201 E. Huron Street, Galter 11-140, Chicago, IL, USA, 60611.
Cochrane Database Syst Rev. 2017 Apr 10;4(4):CD011793. doi: 10.1002/14651858.CD011793.pub2.
Aortic valve disease is a common condition that is easily treatable with cardiac surgery. This is conventionally performed by opening the sternum longitudinally down the centre ("median sternotomy") and replacing the valve under cardiopulmonary bypass. Median sternotomy is generally well tolerated, but as less invasive options have become available, the efficacy of limited incisions has been called into question. In particular, the effects of reducing the visibility and surgical access has raised safety concerns with regards to the placement of cannulae, venting of the heart, epicardial wire placement, and de-airing of the heart at the end of the procedure. These difficulties may increase operating times, affecting outcome. The benefits of smaller incisions are thought to include decreased pain; improved respiratory mechanics; reductions in wound infections, bleeding, and need for transfusion; shorter intensive care stay; better cosmesis; and a quicker return to normal activity.
To assess the effects of minimally invasive aortic valve replacement via a limited sternotomy versus conventional aortic valve replacement via median sternotomy in people with aortic valve disease requiring surgical replacement.
We performed searches of CENTRAL, MEDLINE, Embase, clinical trials registries, and manufacturers' websites from inception to July 2016, with no language limitations. We reviewed references of identified papers to identify any further studies of relevance.
Randomised controlled trials comparing aortic valve replacement via a median sternotomy versus aortic valve replacement via a limited sternotomy. We excluded trials that performed other minimally invasive incisions such as mini-thoracotomies, port access, trans-apical, trans-femoral or robotic procedures. Although some well-conducted prospective and retrospective case-control and cohort studies exist, these were not included in this review.
Two review authors independently assessed trial papers to extract data, assess quality, and identify risk of bias. A third review author provided arbitration where required. The quality of evidence was determined using the GRADE methodology and results of patient-relevant outcomes were summarised in a 'Summary of findings' table.
The review included seven trials with 511 participants. These included adults from centres in Austria, Spain, Italy, Germany, France, and Egypt. We performed 12 comparisons investigating the effects of minimally invasive limited upper hemi-sternotomy on aortic valve replacement as compared to surgery performed via full median sternotomy.There was no evidence of any effect of upper hemi-sternotomy on mortality versus full median sternotomy (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.36 to 2.82; participants = 511; studies = 7; moderate quality). There was no evidence of an increase in cardiopulmonary bypass time with aortic valve replacement performed via an upper hemi-sternotomy (mean difference (MD) 3.02 minutes, 95% CI -4.10 to 10.14; participants = 311; studies = 5; low quality). There was no evidence of an increase in aortic cross-clamp time (MD 0.95 minutes, 95% CI -3.45 to 5.35; participants = 391; studies = 6; low quality). None of the included studies reported major adverse cardiac and cerebrovascular events as a composite end point.There was no evidence of an effect on length of hospital stay through limited hemi-sternotomy (MD -1.31 days, 95% CI -2.63 to 0.01; participants = 297; studies = 5; I = 89%; very low quality). Postoperative blood loss was lower in the upper hemi-sternotomy group (MD -158.00 mL, 95% CI -303.24 to -12.76; participants = 297; studies = 5; moderate quality). The evidence did not support a reduction in deep sternal wound infections (RR 0.71, 95% CI 0.22 to 2.30; participants = 511; studies = 7; moderate quality) or re-exploration (RR 1.01, 95% CI 0.48 to 2.13; participants = 511; studies = 7; moderate quality). There was no change in pain scores by upper hemi-sternotomy (standardised mean difference (SMD) -0.33, 95% CI -0.85 to 0.20; participants = 197; studies = 3; I = 70%; very low quality), but there was a small increase in postoperative pulmonary function tests with minimally invasive limited sternotomy (MD 1.98 % predicted FEV1, 95% CI 0.62 to 3.33; participants = 257; studies = 4; I = 28%; low quality). There was a small reduction in length of intensive care unit stays as a result of the minimally invasive upper hemi-sternotomy (MD -0.57 days, 95% CI -0.93 to -0.20; participants = 297; studies = 5; low quality). Postoperative atrial fibrillation was not reduced with minimally invasive aortic valve replacement through limited compared to full sternotomy (RR 0.60, 95% CI 0.07 to 4.89; participants = 240; studies = 3; moderate quality), neither were postoperative ventilation times (MD -1.12 hours, 95% CI -3.43 to 1.19; participants = 297; studies = 5; low quality). None of the included studies reported cost analyses.
AUTHORS' CONCLUSIONS: The evidence in this review was assessed as generally low to moderate quality. The study sample sizes were small and underpowered to demonstrate differences in outcomes with low event rates. Clinical heterogeneity both between and within studies is a relatively fixed feature of surgical trials, and this also contributed to the need for caution in interpreting results.Considering these limitations, there was uncertainty of the effect on mortality or extracorporeal support times with upper hemi-sternotomy for aortic valve replacement compared to full median sternotomy. The evidence to support a reduction in total hospital length of stay or intensive care stay was low in quality. There was also uncertainty of any difference in the rates of other, secondary outcome measures or adverse events with minimally invasive limited sternotomy approaches to aortic valve replacement.There appears to be uncertainty between minimally invasive aortic valve replacement via upper hemi-sternotomy and conventional aortic valve replacement via a full median sternotomy. Before widespread adoption of the minimally invasive approach can be recommended, there is a need for a well-designed and adequately powered prospective randomised controlled trial. Such a study would benefit from performing a robust cost analysis. Growing patient preference for minimally invasive techniques merits thorough quality-of-life analyses to be included as end points, as well as quantitative measures of physiological reserve.
主动脉瓣疾病是一种常见病症,可通过心脏手术轻松治疗。传统上,该手术通过沿胸骨正中纵向切开(“正中胸骨切开术”)并在体外循环下置换瓣膜来进行。正中胸骨切开术一般耐受性良好,但随着侵入性较小的手术方式出现,有限切口手术的疗效受到质疑。特别是,减少视野和手术入路所带来的影响引发了对插管放置、心脏排气、心外膜导线放置以及手术结束时心脏排气的安全担忧。这些困难可能会延长手术时间,影响手术结果。较小切口的益处被认为包括减轻疼痛;改善呼吸力学;减少伤口感染、出血和输血需求;缩短重症监护时间;改善美观效果;以及更快恢复正常活动。
评估对于需要进行手术置换的主动脉瓣疾病患者,经有限胸骨切开术进行微创主动脉瓣置换与经正中胸骨切开术进行传统主动脉瓣置换的效果。
我们检索了Cochrane系统评价数据库(CENTRAL)、医学期刊数据库(MEDLINE)、荷兰医学文摘数据库(Embase)、临床试验注册库以及制造商网站,检索时间从建库至2016年7月,无语言限制。我们查阅了已识别论文的参考文献,以确定任何其他相关研究。
比较经正中胸骨切开术与经有限胸骨切开术进行主动脉瓣置换的随机对照试验。我们排除了进行其他微创切口(如小切口开胸术、端口入路、经心尖、经股动脉或机器人手术)的试验。尽管存在一些设计良好的前瞻性和回顾性病例对照研究及队列研究,但本综述未纳入这些研究。
两位综述作者独立评估试验论文以提取数据、评估质量并识别偏倚风险。如有需要,第三位综述作者进行仲裁。使用GRADE方法确定证据质量,并在“结果总结”表中总结与患者相关结局的结果。
本综述纳入了7项试验,共511名参与者。这些参与者来自奥地利、西班牙、意大利、德国、法国和埃及的中心。我们进行了12项比较,研究与经全正中胸骨切开术相比,微创有限上半胸骨切开术对主动脉瓣置换的影响。没有证据表明上半胸骨切开术与全正中胸骨切开术相比对死亡率有任何影响(风险比(RR)1.01,95%置信区间(CI)0.36至2.82;参与者 = 511;研究 = 7;中等质量)。没有证据表明经上半胸骨切开术进行主动脉瓣置换会增加体外循环时间(平均差(MD)3.02分钟,95% CI -4.10至10.14;参与者 = 311;研究 = 5;低质量)。没有证据表明主动脉阻断时间会增加(MD 0.95分钟,95% CI -3.45至5.35;参与者 = 391;研究 = 6;低质量)。纳入的研究均未将主要不良心脑血管事件作为复合终点报告。没有证据表明有限上半胸骨切开术对住院时间有影响(MD -1.31天,95% CI -2.63至0.01;参与者 = 297;研究 = 5;I² = 89%;极低质量)。上半胸骨切开术组术后失血量较低(MD -158.00 mL, 95% CI -303.24至 -12.76;参与者 = 297;研究 = 5;中等质量)。证据不支持减少深部胸骨伤口感染(RR 0.71,95% CI 0.22至2.30;参与者 = 511;研究 = 7;中等质量)或再次手术(RR 1.01,95% CI 0.48至2.13;参与者 = 511;研究 = 7;中等质量)。上半胸骨切开术对疼痛评分没有影响(标准化均差(SMD)-0.33,95% CI -0.85至0.20;参与者 = 197;研究 = 3;I² = 70%;极低质量),但微创有限胸骨切开术术后肺功能测试有小幅改善(MD 预测FEV1增加1.98%,95% CI 0.62至3.33;参与者 = 257;研究 = 4;I² = 28%;低质量)。由于微创上半胸骨切开术,重症监护病房住院时间略有缩短(MD -0.57天,9�% CI -0.93至 -0.20;参与者 = 297;研究 = 5;低质量)。与全胸骨切开术相比,经有限胸骨切开术进行微创主动脉瓣置换术后房颤并未减少(RR 0.60,95% CI 0.07至4.89;参与者 = 240;研究 = 3;中等质量),术后通气时间也没有减少(MD -1.12小时, 95% CI -3.43至1.19;参与者 = 297;研究 = 5;低质量)。纳入的研究均未报告成本分析。
本综述中的证据质量总体评估为低到中等。研究样本量较小,不足以证明在低事件发生率下结局的差异。研究之间和研究内部的临床异质性是外科试验相对固定的特征,这也导致在解释结果时需要谨慎。考虑到这些局限性,与全正中胸骨切开术相比,上半胸骨切开术用于主动脉瓣置换对死亡率或体外循环支持时间的影响存在不确定性。支持缩短总住院时间或重症监护时间的证据质量较低。对于微创有限胸骨切开术式的主动脉瓣置换,在其他次要结局指标或不良事件发生率方面是否存在差异也存在不确定性。经上半胸骨切开术进行微创主动脉瓣置换与经全正中胸骨切开术进行传统主动脉瓣置换之间似乎存在不确定性。在推荐广泛采用微创方法之前,需要进行一项设计良好且样本量充足的前瞻性随机对照试验。这样的研究将受益于进行强有力的成本分析。患者对微创技术的偏好日益增加,这值得将全面的生活质量分析作为终点纳入研究,同时纳入生理储备的定量测量。